What Is NAD, Answered From Our NMN and NR Grades

Ask what NAD is and most pages answer with a shopping list. The molecule comes first here, then the two supplements that claim to raise it, graded on the human evidence in our library: NMN at C+ and nicotinamide riboside (NR) at B-. The grades differ, and the reason they differ is the whole answer.

The molecule

NAD, nicotinamide adenine dinucleotide in full, is a coenzyme found in every living cell. It shuttles electrons in the reactions that turn food into usable energy, and it is consumed by enzymes that repair DNA and regulate gene expression, the sirtuins and PARPs of the longevity literature. Your body makes it from dietary building blocks, vitamin B3 forms and the amino acid tryptophan, and recycles it continuously.

Two facts about NAD are routinely blurred in the marketing. First, you cannot swallow NAD itself and expect it to arrive: the molecule is broken down in digestion, which is why the entire category sells precursors instead. Second, NAD blood levels are a measurement rather than an outcome: a higher level is a chemistry result, and whether it makes a person healthier, stronger, or longer-lived is a separate question with separate evidence, which is why grading keeps the two halves apart.

The premise underneath the category

The sales pitch runs on a decline story: NAD falls as you age, so restore it. In May 2026 a paper in Nature Metabolism measured whole blood NAD by mass spectrometry across seven independent human cohorts and found levels stable across age, frailty, athletic status, and lifestyle interventions including exercise and diet, rising appreciably only after NR supplementation. The limit rides with the finding, and our records carry it: blood is not tissue, levels inside muscle or brain could move differently, and nobody's outcome was measured. But the premise as sold, a blood level in free fall that a capsule restores, is not what the best measurement found. The category's foundation is weaker than its shelf talk.

NMN: the level is proven, the benefit is not

NMN, nicotinamide mononucleotide, is one step from NAD in the body's own pathway. On the biomarker half, the evidence has become genuinely strong. A randomized trial published in January 2026 found that 1,000 mg a day roughly doubled blood NAD within 14 days. A University of Tokyo trial in 62 older adults sustained the elevation across 24 weeks. Multiple trials now agree: NMN raises the level.

On the outcome half, the same literature goes quiet. The Tokyo trial found no effect on its primary functional outcomes. A 2026 meta-analysis of 15 NMN trials found no broad metabolic benefit. One smaller trial, in overweight prediabetic postmenopausal women, found improved muscle insulin sensitivity at 250 mg a day over ten weeks, a real signal that has not been replicated broadly. That is the record behind our grade: C+ on the evidence, C- on worth-it at $30 to $60 a month. Biomarker strong, outcomes thin is not a slogan but the shape of the file.

NR: deeper evidence, same missing half

NR enters the pathway one step earlier and has been studied in humans longer and harder, which is why it grades higher at B-. Trials at 300 to 1,000 mg a day raise blood NAD by roughly 50 to over 140 percent. It is also the precursor with the category's largest rigorous test, and that test is the sobering part: NOPARK randomized 410 people with Parkinson's disease and missed its primary endpoint. NR did not slow the disease it was meant to help. Smaller positive signals exist, including a small company-sponsored trial in long COVID symptom scores, and they are graded as what they are: small, and company-sponsored.

NR costs the same $30 to $60 a month and grades C on worth-it. The B- buys you a deeper file, including a large null trial honestly recorded. It does not buy a demonstrated longevity benefit, because no precursor has one.

The blood pressure and brain claims, checked against the page

Category marketing adds claims the grades do not carry, and the two most common deserve direct answers. Blood pressure: the suggestion rests on a small NR trial whose blood pressure signal appeared in a subgroup, and no NMN or NR trial since has established a blood pressure effect. It is an unproven claim traveling on a subgroup's clothes. Brain health: the NOPARK result is the strongest brain evidence in the category, and it is null. A reader who takes either precursor for their brain or their blood pressure is spending on the two claims with the least behind them.

What the grades mean for a buyer

If you take a precursor, take it as what the evidence says it is: a reliable way to raise a blood level whose benefit is unproven, at $30 to $60 a month, with a good short-term safety record in trials. Between the two, NR's file is deeper and NMN's recent biomarker trials are strong; neither file contains a positive human trial on a hard outcome. The day one does, the grades move, and this page will say so. Until then, the honest answer to "what is NAD" includes the sentence the category leaves out: the level is measurable, the restoration is real, and the benefit is the part still waiting for its trial.